- Home
- ATXS vs AUTL Comparison
ATXS vs AUTL Comparison
Compare ATXS & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- AUTL
- Stock Information
- Founded
- ATXS 2008
- AUTL 2014
- Country
- ATXS United States
- AUTL United Kingdom
- Employees
- ATXS N/A
- AUTL N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATXS Health Care
- AUTL Health Care
- Exchange
- ATXS Nasdaq
- AUTL Nasdaq
- Market Cap
- ATXS 424.4M
- AUTL 415.2M
- IPO Year
- ATXS 2015
- AUTL 2018
- Fundamental
- Price
- ATXS $7.52
- AUTL $1.61
- Analyst Decision
- ATXS Buy
- AUTL Strong Buy
- Analyst Count
- ATXS 6
- AUTL 5
- Target Price
- ATXS $33.00
- AUTL $9.12
- AVG Volume (30 Days)
- ATXS 436.6K
- AUTL 4.9M
- Earning Date
- ATXS 11-12-2025
- AUTL 11-11-2025
- Dividend Yield
- ATXS N/A
- AUTL N/A
- EPS Growth
- ATXS N/A
- AUTL N/A
- EPS
- ATXS N/A
- AUTL N/A
- Revenue
- ATXS N/A
- AUTL $29,934,000.00
- Revenue This Year
- ATXS N/A
- AUTL $641.63
- Revenue Next Year
- ATXS N/A
- AUTL $109.21
- P/E Ratio
- ATXS N/A
- AUTL N/A
- Revenue Growth
- ATXS N/A
- AUTL 185.17
- 52 Week Low
- ATXS $3.56
- AUTL $1.11
- 52 Week High
- ATXS $12.52
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- ATXS 55.75
- AUTL 53.15
- Support Level
- ATXS $6.95
- AUTL $1.56
- Resistance Level
- ATXS $7.48
- AUTL $1.70
- Average True Range (ATR)
- ATXS 0.42
- AUTL 0.09
- MACD
- ATXS -0.01
- AUTL 0.05
- Stochastic Oscillator
- ATXS 65.35
- AUTL 79.73
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.